|Referral date||01 July 2009|
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|1 April 2010||
This technology appraisal was formally referred to the Institute as part of the 21st wave work programme. The remit was as follows:
To appraise the clinical and cost effectiveness of interferon beta-1b, interferon beta-1a and glatiramer acetate within their licensed indications for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32).
TA32 is currently regarded as ‘static’ guidance and the Institute is of the opinion that this is still appropriate. As a result, this appraisal will not commence at this time due to the remit specifically indicating that it should be included in a review of TA32.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance